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Introduction:  This study aims to examine differences between outer regional (OR) and 
remote/very remote (RVR) patients in northern Queensland, Australia, in the times taken to 
receive various aspects of head and neck cancer management. 
Methods: Our study prospectively recruited head and neck cancer patients presenting to three 
North Queensland regional hospitals from 1/2009 to 1/2011.  Data on demographic and 
cancer specific details, co-morbidities and timing of presentation to various services were 
collected using a self-administered questionnaire that included two questions in relation to 
possible reason for delays to health services. Multivariate linear regression analyses were 
conducted to assess the effects of various demographic characteristics on time delays.  
Survival and disease recurrence data were analysed in 2014.  
Results: 158 patients participated.  RVR patients had significantly longer median times 
between diagnosis and first treatment compared with OR patients (p=0.015). Indigenous 
patients had significant delays from diagnosis to first treatment (p=0.013) and visit to first 
specialist and treatment (p=0.031) compared to non-Indigenous patients.  Longer median 
times between symptoms and first treatment associated with low income (p=0.03) and lower 
education level (p=0.04).  Disease recurrence was higher for RVR patients compared with 
OR patients (p=0.04), without significant differences in overall survival. Possible reasons for 
delays included patient and professional factors. 
Conclusions: Significant delays in various aspects of head and neck cancer management 
were associated with remoteness, Indigenous and socioeconomic status. While patient and 
professional factors could be addressed at local levels, it requires a state and national level 
approach for sustainable improvement in outcomes. 
Key words: Head and neck cancer, rural health, diagnosis delay, treatment delay 












ASGC = Australian Standard Geographical Classification 
CI = Confidence Interval 
ECOG = Eastern Cooperative Oncology Group 
ENT = Ear, Nose and Throat (Otolaryngology) Surgeon 
OR = Outer Regional  
RVR = Remote / Very Remote 
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remote/very remote (RVR) patients in northern Queensland, Australia, in the times taken to 
receive various aspects of head and neck cancer management. 
Methods: Our study prospectively recruited head and neck cancer patients presenting to three 
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OR patients (p=0.04), without significant differences in overall survival. Possible reasons for 
delays included patient and professional factors. 
Conclusions: Significant delays in various aspects of head and neck cancer management 
were associated with remoteness, Indigenous and socioeconomic status. While patient and 
professional factors could be addressed at local levels, it requires a state and national level 






Head and neck cancer describes a range of cancers to the oral cavity, salivary glands, nasal 
cavity, sinuses, pharynx and larynx 1-4. The most common histological type is squamous cell 
carcinoma1-4.   Despite recent advances in treatment, mortality and morbidity rates continue 
to be high, particularly for rural and remote patients 3, 5. These high rates may be due to a 
number of factors, including delays in diagnosis and treatment 6. Between 2006-2010, the 
overall five -year survival rate for head and neck cancer patients in Australia was 68.2%.3 
People living in regional and remote areas of Australia have poorer health outcomes 
including lower survival rates when compared to their city counterparts7-10. Some of the 
suggested reasons for this disparity include increased cancer risk factors, including smoking, 
alcohol consumption and sun exposure amongst people in regional and remote areas7-10. 
Other reasons may include socio-economic factors and poorer access to health care services8.   
The rural/remote disadvantage is particularly evident in Australia with its large geographical 











area and relatively small population.   Health services are often stretched to the limit in rural 
and remote areas.   North Queensland encompasses a very large geographical area 
~740000km2 (~43% of Queensland) but serves a population of only ~600000, (~15% of the 
total population of Queensland)11.  This large area is serviced by three tertiary hospitals in 
Townsville, Cairns, and Mackay, with the main specialist centre in Townsville. 
The usual management pathway for head and neck cancer begins with the patient presenting 
to their general practitioner (primary health care physician) following symptoms1, 2, 12, 13.   
Generally after clinical review, imaging scans are undertaken prior to referral to specialists 
(e.g. surgeons and/or interventional radiologists) for biopsy and further management.  Once a 
diagnosis is confirmed, the patients are referred to head and neck multidisciplinary meetings 
and clinics (ENT surgeons, radiation oncologists, medical oncologists) where optimal 
treatment is planned.   Treatments may include surgical excision, radiation therapy, 
chemotherapy and/or a combination of these 1, 2.  Treatment may be either with curative or 
palliative (for symptom relief) intent.        
Delays in treatment can be classified according to ‘patient’ or ‘professional’ delays 6, 13. 
Patient delays are where patient factors cause delays from the onset of their first symptoms 
until presentation to a health care provider for treatment (e.g. patients dismissing their 
symptoms until at an advanced stage)6, 13.  Professional delays are those where there are 
health care provider delays from consultation to diagnosis to treatment 6, 13  (e.g. delay until 
treatment such as surgery or radiation able to be booked and performed).  The average patient 
delays ranged from 1.0 to 5.4 months and the average professional delays from 3 to 21 weeks 
6, 13. The majority of published studies were retrospective case control studies that aimed to 
identify risk factors and their impact on stage of disease at presentation 6, 12, 13.     











The identification of specific barriers to health services will inform the development of 
strategies to improve health outcomes for patients from rural and remote areas.  There is a 
paucity of literature that explores the specific delays patients from rural and remote areas 
with head and neck cancer experience in the Australian setting.   This study aims to examine 
the differences between patients from outer regional areas and those from remote areas in the 
time taken to receive head and neck cancer management by the North Queensland Cancer 
Care Services.   
  












Participants and Recruitment 
Newly diagnosed head and neck cancer patients presenting to the Townsville, Cairns and 
Mackay Hospitals were prospectively recruited over a 24-month period from 1/2009 to 
1/2011 following identification through specialist outpatient clinics and multidisciplinary 
head and neck team meetings and informed consent. Ethics approval was granted by the 
participating health services.  
Data Collection 
Data was collected through self-administered questionnaires as well as review of medical 
records, pathology reports and the existing MOSAIQ™ clinical oncology database which is 
used for integrated cancer services provision. The questionnaire included the following 
details: 
(1) Demographic and socio-economic details such as age, gender, ethnicity, Indigenous 
status, gross household income, highest level of education, living arrangements, employment, 
private health insurance and place of residence.   
(2) Distance from home to the General Practitioner, local hospital, nearest specialist for 
surgery, chemotherapy, radiation therapy and palliative care.  
(3) Co-morbidities, medications, pre-diagnosis symptoms and performance status.  
(4) Dates of first presentation to a general practitioner, investigations, specialist reviews and 
treatment.  Remoteness was classified according to Australian Standard Geographical 
Classification (ASGC) remoteness classification into outer regional and remote/very remote 
categories14. 











At the end of the questionnaire, patients were asked to respond to two short answer questions  
“why was there a delay in reporting your first symptoms to a doctor?” and Why do you think 
you felt it too difficult to get treatment?”.  Survival and disease recurrence data was examined 
at April 2014.  Patients were classified as lost to follow up if there was no patient information 
recorded since September 2013.  
Data Analysis 
We used the Statistical Package for Social Sciences (SPSS v22) for analysis. Fisher’s test was 
used to identify differences between the outer regional and remote/very remote cohorts.   
Kruskal-Wallis and Mann-Whitney tests were used to calculate the p-values when examining 
differences in time delays experienced between stage, Indigenous status, and socio-economic 
status.  Chi squared tests were used for survival and disease recurrence data.   Multivariable 
linear regression analyses were conducted to assess the effects of demographic characteristics 
(age, gender, Indigenous status, level of education, employment status, living arrangement, 
number of dependents, private health insurance, synchronous and previous cancer, and 
income) on time delays.  Times were logarithmically transformed to achieve approximate 
normal distributions. Statistically significant influencing factors were identified using 
backward and forward modelling processes. Remaining characteristics were checked for 
potential confounding factors (changes in estimator by at least 5%). Models were adjusted for 
identified confounders. Data was also analysed according to whether the patient was from 
Townsville (the main tertiary hospital), Mackay or Cairns (both smaller, hospitals), compared 
with other remote areas.  The stage of head and neck cancer, gender, age (<50, 51 to 70, >70) 
Indigenous status and socioeconomic status (gross household income, highest level of 
education) were also examined. 
 












One hundred and fifty-eight (158) head and neck cancer patients were identified from 
January 2009 to January 2011 (Table 1). All of these patients had squamous cell carcinomas.   
The majority of patients had advanced disease, with 33 patients (21%) stage III,  and 83 
patients (52%)  stage IV at the time of diagnosis.  In our study group, stage IV head and 
neck cancers included patients who had locoregionally advanced disease without 
evidence of distant metastasis and were treated with curative intent. One hundred and 
eighteen (118) patients (75.3%) received curative intent treatment and 40 patients (25%) 
received palliative treatment (Table 1). Sites of primary cancer and corresponding patient 
numbers are as follow: oral cavity 83 (53%), pharynx 30   (19.0%), larynx 26 (15.6%), salivary 
glands 12 (6.8%) and nasal cavity and paranasal sinus 7 (4.3%). Top five predominant 
symptoms (with corresponding patient numbers) were pain (99), obvious lump (85), 
dysphagia (81), voice change (57) and sore throat (54). No differences in the distribution of 
sites of primary cancer or symptoms were observed between rural and urban groups. 
 
Upon further analysis in 2014, with follow up between 3 – 5 years, overall 83 patients 
(52.5%) were alive, 10 patients (6.3%) were lost to follow up and 65 patients (41.1%) had 
died.  Of the curative treatment group, 31 patients (26.3%) had died. The median survival 
time of these 31 deceased patients was 20.5 months (overall median survival not yet reached 
with >50% alive).  Twenty (20) curative intent patients (16.9%) had disease recurrence.  The 
median time to disease recurrence was 9 months (range 4- 43 months).   
Ninety-eight patients (62%) were living in outer regional areas and 59 patients (37%) in 
remote /very remote areas. One patient identified from a metropolitan area.   More 
Caucasians were living in outer regional areas (89.9%), compared to those in remote/very 











remote areas (76.3%). There was no significant difference between TNM stage and whether 
patients were from outer regional or remote/very remote areas.  Patients living in remote/very 
remote areas compared to outer regional areas experienced significantly longer median times 
between diagnosis and first treatment (p=0.015).  There was a significant difference in 
disease recurrence for patients living in remote/very remote areas with 11/31 (35.5%) 
compared with patients from outer regional areas 8/56 (14.3%) [Odds ratio 3.30] (CI 1.15 to 
9.42, p = 0.04).  However, there was no significant difference between mortality for those 
living in outer regional or remote/very remote locations.    
Forty-two (42) patients were identified as living in the Townsville area, forty-one (41) in the 
Cairns or Mackay area, and 75 in other areas. There was a significant difference in median 
times between diagnosis and first treatment (36.5 days, vs 40 days vs 55.5 days,  p=0.012), 
and between first specialist visit and first treatment(35.5 days ,vs 42.5 days vs 55 days, 
p=0.003).  There were no significant differences in mortality or disease recurrence between 
these groups.  (See appendix 1 online for table regarding Townsville vs Cairns/Mackay vs 
Other Areas for more detailed data) 
When compared with non-Indigenous patients, Indigenous patients had significant delays 
from diagnosis to first treatment (p = 0.013) and from their first specialist visit to treatment (p 
= 0.031) (See Table 2).  Sixteen out of twenty-three Indigenous patients (69.6%) presented 
with Stage IV disease.   More Indigenous patients (10/23, 43.5%) had palliative intent 
treatment compared with non-Indigenous patients (30/135, 22.2%). There were no significant 
differences in mortality rates between Indigenous and non-Indigenous patients. 
There was a statistically significant delay in time between onset of symptoms and first 
treatment in patients with lower income compared to those with higher incomes (95% CI, 
0.785 to 0.036, p = 0.032).  Similar results were found in patients with primary or lower level 











of education compared to those with higher education levels (95% CI 0.011 to 0.817, p = 
0.044).  Patients without private health insurance also experienced significant delay in the 
time between diagnosis and first treatment (95% CI, 1.206 to 0.088, p = 0.024).   No 
significant differences in mortality or disease recurrence between patients of different socio-
economic status were found (Table 3).   
Analysis based on TNM stage did not find any significant differences between stage and 
median times between symptoms, first consultation, visit to first specialist, diagnosis and first 
treatment.    Analysis revealed that treatment delays (>30 days) compared to those who had 
earlier treatment, did not result in significant increased mortality or disease recurrence.   
Reason for delays: 
71 patients responded to the two questions in relation the reason for delays. Reasons and 
corresponding patient numbers are outlined as follow: 
Presentation to primary care: 
Patients had known that there was something serious but presented late due to the hope that it 
would go away (34), flooding and cyclone (5) and patients attributing their symptoms to 
other causes (1) 
Delay in specialist services: 
Delayed referral by general practitioner due to loss of referral (6), patients failing to attend 
appointments (9), patients undecided about treatment (9), investigation of other co-
morbidities (7) and delay in booking surgery (3). No formal comparison between rural and 
urban patients was conducted due small patient numbers in each subgroup. 
 













We believe this is the first Australian prospective study to examine the differences between 
regional, and remote/very remote head and neck cancer patients’ diagnostic, referral and 
management pathways.  Our study found significantly longer times to first treatment for 
remote/very remote patients when compared to those in regional areas.   Patients from remote 
locations had a trend to longer median times across all aspects of management of their head 
and neck cancer, although not all aspects reached statistical significance.    The delays in 
presentation was not reflected by significant differences in stage of cancer at diagnosis.  
Disease recurrence was significantly greater in the remote/very remote group compared to the 
outer regional group; however, this finding did not translate to statistically significant 
differences in survival rates.   A larger cohort of patients and longer follow up times may be 
needed to demonstrate any survival differences.  
Although the number of Indigenous patients in our study was small, results indicated that 
these patients were significantly more likely to receive only palliative treatment. More 
Indigenous, than non-Indigenous patients, presented with Stage IV disease.  Delays to 
presentation to health services are likely to lead to later stage disease at diagnosis. There 
appeared to be a trend towards longer median time between symptoms and first consultation, 
however, this finding did not reach statistical significance.    The time between diagnosis and 
first treatment, and first specialist visit and treatment were statistically significantly longer in 
this patient cohort.  Having palliative treatment only may add to the delay in time to first 
treatment due to the lack of urgency for palliative treatment.   











Indigenous patients have been shown to have poorer health outcomes compared to non-
indigenous patients 15, 16 .  Indigenous liaison officers help provide support and education to 
patients but ongoing work is needed to help bridge the gap.   
Overall, the patient delays reported in our study at 62 days (with a wide range from 0 to 647 
days), were similar to those reported in other studies (1.0 – 5.4 months (ie. 30 – 160 days)) 6, 
13.  At least 22% of our patients either assumed that the symptoms would go away or 
attributed their symptoms to other causes. Our estimated total professional delay from first 
consultation to first treatment was 94 days (range 2 - 794 days).   This delay is consistent 
with other reports of professional delays of 3 to 21 weeks (i.e. 21 to 147 days)6, 13.  Once 
diagnosis was confirmed, the median time to first treatment was 42 days (range 0 to 429 
days).   In our study, nearly 10% of our patients experienced delays due to loss of referral or 
failure to attend clinics due to misunderstanding. Longer professional delay may be 
influenced by patient preferences as well as to when their treatment begins. This issue may be 
of particular relevance in the case of palliative treatment.  Our total median time delay 
between symptoms and first treatment in our study was 216.5 days.  
Delays in treatment are often thought to confer worse outcomes,  however, there are some 
conflicting reports.  A Dutch study17  reported that treatment delay up to 90 days in head and 
neck squamous cell carcinomas was not associated with worse prognosis in terms of survival 
or disease recurrence.  A recent meta-analysis found that diagnostic delay increased the 
mortality of head and neck cancer patients by a factor of 1.34 and referral delay increased 
mortality by three times, although the overall mortality was not significantly increased6. 
As the majority of the patients in our study had advanced disease (stage IV - 52.9%), and we 
included a variety of tumour sites, our survival rate of 53.5% at 3 years, and disease 
recurrence rate of 16.9%, appears to be roughly equivalent with other centres.  Most studies 











however report 5 year survival (not 3 year) and report on specific tumour sites.  The Oxford 
Cancer Intelligence Unit reported the three year survival rate for head and neck cancers in 
England varied from 33 to 75% depending on tumour site18.     
One of the issues regional and remote cancer patients experience is timely access to specialist 
treatment.  A recent study looked at Head and Neck outcomes in centres with high volumes 
of patients accrued in clinical trials vs centres with low volumes of patients, and found that 
overall survival was worse for the centres with low volumes of patients even after adjustment 
for prognostic factors and radiotherapy compliance19.  While it is desirable to have treatment 
at high volume specialist centres, this is not always practical and may further contribute to 
treatment delays.  Townsville is the major head and neck cancer centre for the North 
Queensland district.  The next major referral centre is located in Brisbane approximately 
1350km away.   
Despite awareness of the rural/remote disparity, there has been little progress in overcoming 
the rural/remote disadvantage in terms of cancer death rates 7-10.   Various Australian studies, 
have identified factors contributing to the excessive cancer deaths in regional and remote  
areas such as higher proportions of Indigenous people, greater economic disadvantage 
associated with some regional and remote locations, a higher prevalence of cancer risk 
factors, less cancer screening, delays in seeking medical attention and/or delays in diagnosis, 
higher prevalence of comorbid conditions and treatment disparities8.  Some possible 
strategies to help bridge the rural/regional divide include greater support for regional and 
remote patients to travel, better managed referral pathways, various specialist outreach 
models of care such as “fly in fly out” specialists, timely processing of referrals, virtual 
multidisciplinary teams coordinated by care coordinators, building the capacity of local staff 
in regional cancer services and telemedicine8. 











Telemedicine is the delivery of medical consultations using videoconferencing and other 
information and communication technologies. Telemedicine has the advantage of bringing 
the specialist consultations to the patients in their local communities, allowing the patient to 
avoid travelling long distances to the centre and allowing them to remain at home with their 
support network 19.  This may assist with expediting timely diagnosis and treatment and 
follow up.   
Addressing rural healthcare workforce shortages is important in order to bridge the 
regional/remote divide. Increasing the number of adequately trained medical, nursing and 
other health care professionals in Australia may translate to more health services for regional, 
rural and remote communities.   Education of primary healthcare workers on head and neck 
cancers may lead to more timely consultations, diagnosis and treatment  
Another area for further study is to examine whether there are differences in the percentage 
of P16 positivity (Human Papilloma Virus (HPV) associated) head and neck cancers between 
rural/remote cohorts compared to their metropolitan counterparts.  P16 positive head and 
neck tumours have been found to have better prognostic outcomes 20.  Whether this risk 
factor/pathogenesis differences between rural/remote cohorts compared to their metropolitan 
counterparts, accounts for some of the disparities is yet to be explored.   
In conclusion, our study demonstrated delays in various aspects of head and neck cancer 
management associated with geographical remoteness and other socio-economic factors and 
attempted to identify possible reasons for these delays. While some patient and professional 
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Demographic     
Male 130 (82.3%) 82 (82.8%) 48 (81.4%) P=0.832 
Mean age (SD)***; range [years] 60.9 (12.4); 26 to 89 61.1 (12.7); 26 to 89 60.7 (12.0); 31 to 89 P=0.852 
Caucasian 134 (84.8%) 89 (89.9%) 45 (76.3%) P=0.037 
Born in Australia 131 (83.4%) 80 (80.8%) 51 (87.9%) P=0.275 
Secondary or higher school education; n=121 90 (74.4%) 63 (79.7%) 27 (64.3%) P=0.140 
Employed 77 (48.7%) 46 (46.5%) 31 (52.5%) P=0.288 
Living alone 52 (32.9%) 32 (32.3%) 20 (33.9%) P=0.207 
With dependants 24 (15.2%) 16 (16.2%) 8 (13.6%) P=0.819 
Private health insurance 54 (34.2%) 29 (29.3%) 25 (42.4%) P=0.260 
Income protection cover 2 (1.3%) 2 (2.0%) 0 (0%) P=0.529 
Life insurance 19 (12.0%) 14 (14.1%) 5 (8.5%) P=0.325 
Income less then $20,000; n=107 42 (39.3%) 23 (35.4%) 19 (45.2%) P=0.320 
     
Diagnosis     
Incidental finding 11 (7.0%) 6 (6.1%) 5 (8.5%) P=0.748 






















Treatment palliative 40 (25.3%) 27 (27.3%) 13 (22.0%) P=0.571 
     











Time delays experienced     
Median time between symptoms and first 
consultation (IQR)^; range [days]; n=145 
62  
(31, 171.5);  
0 to 647  
61  
(31, 153);  
0 to 647  
90.5  
(31, 181.25); 0 to 485 
P=0.762 
Median time between symptoms and referral to 
first specialist (IQR); range [days]; n=143 
148  
(73, 211);  
2 to 803  
121  
(70, 212.75); 2 to 
803  
168  
(96, 201);  
13 to 791  
P=0.252 
Median time between symptoms and visit of 
first specialist (IQR); range [days]; n=147 
155  
(88, 155);  
5 to 833  
132  
(81, 235);  
5 to 833  
181  
(99, 213.25); 26 to 
831  
P=0.298 
Median time between symptoms and first 
treatment (IQR); range [days]; n=140 
216.5  
(134, 303);  
0 to 904  
200  
(129, 311);  
9 to 854  
221  
(144.75, 302.5);  
0 to 904  
P=0.441 
Median time between diagnosis and first 
treatment (IQR); range [days]; n=145 
42  
(26, 66.5);  
0 to 429  
37.5  
(18.25, 62); 0 to 
420  
53  
(33.5, 75.5);  
0 to 429  
P=0.015 
Median time between first consultation and 
referral to first specialist (IQR); range [days]; 
n=150 
26  
(6, 66.75);  
0 to 741  
24  
(6, 62);  
0 to 741  
30  
(10, 72);  
0 to 463  
P=0.462 
Median time between visit of first specialist and 
treatment (IQR); range [days]; n=145 
 
45  
(28.5, 73);  
0 to 244  
42  
(27.25, 59.25);  
0 to 223  
49  
(31, 76.5);  
0 to 244  
 
P=0.132 
     
Mortality- overall 65/158(41.1%) 37/99 (37.4%) 28/59 (47.4%) 0.24 
Mortality – curative patients 31/118(26.3%) 19/70 (27.1%)   12/49 (24.5%) 0.83 
Disease Recurrence - curative patients 20/118(16.9%) 8/56 (14.3%) 11/31 (35.5%)   0.04 
     
*Includes one person from a major city; **p‐values are results of Fisher’s exact tests, unpaired t‐tests, and 
Mann‐Whitney tests; ***SD = standard deviation; ^IQR = inter‐quartile range. 












Table 2.  Indigenous patients 
 Indigenous   





Median time between symptoms and 




0 to 485 
92 
(47.5, 181); 
13 to 647 
P=0.218 P=0.236 
Median time between symptoms and 




2 to 791 
175 
(80, 209); 
13 to 803 
P=0.472 P=0.514 
Median time between symptoms and 




5 to 831 
181 
(88, 240); 
26 to 833 
P=0.501 P=0.546 
Median time between symptoms and 




0 to 904 
246.5 
(167.25, 327); 
96 to 854 
P=0.129 P=0.173 
Median time between diagnosis and 




0 to 429 
69.5 
(35.75, 109); 
0 to 420 
P=0.013 P=0.027 
Median time between first consultation 
and referral to first specialist (IQR); 
range [days]; n=150 
26 
(7, 72); 
0 to 741 
19 
(0, 45.25); 
0 to 463 
P=0.329 P=0.260 
Median time between visit of first 
















     











     
Palliative treatment 29/135(21.4%) 10/23 (43.5%) 0.03  
     
Mortality 54/135 11/23 (47.8%)  0.5  
 (40%)    
     
Disease recurrence 20/99 (20.2%) 0/12 0.12  
     
^IQR = inter-quartile range; *First p-value is result of Mann-Whitney test;** Second p-value 

































Logarithmic time delays 
experienced 
Influencing factor Coefficient 95%-confidence 
interval 
p-value 
Time between symptoms and first 
consultation  
None    
     
Time between symptoms and 
referral to first specialist  
None    
     
Time between symptoms and visit 
of first specialist  
None    
     
Time between symptoms and first 
treatment* 













 Level of education 
Primary or lower 
Secondary level 













     
Time between diagnosis and first 
treatment** 
    
 Private health insurance 
No 

































Very remote 0.637 -0.488, 1.762 P=0.264 
     
Time between first consultation and 
referral to first specialist*** 
    
 Location of residence 
Townsville 














     
Time between visit of first specialist 
and treatment^ 
    
 Location of residence 
Townsville 
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